HALOZYME REPORTS THIRD QUARTER 2022 FINANCIAL AND OPERATING RESULTS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/15/2026
- Wall St ends higher on cool inflation data, strong earnings
- U.S. headline producer inflation posts first one-month decrease since August 2025
- PayPal rallies 20% on report Stripe, Advent made $53 billion bid
- Oil prices make small gain on smaller US inventory draw
- ASML capacity upgrade soothes AI chip bottleneck fears
Halozyme Therapeutics (HALO) Tops Q3 EPS by 42c
November 8, 2022 4:11 PM ESTHalozyme Therapeutics (NASDAQ: HALO) reported Q3 EPS of $0.74, $0.42 better than the analyst estimate of $0.32. Revenue for the quarter came in at $209 million versus the consensus estimate of $189.72 million.
GUIDANCE:
Halozyme Therapeutics sees FY2022 revenue of $655-685 million, versus the consensus of... More
